Ginkgo Bioworks Holdings, Inc. (DNA) AI Stock Summary

Snapshot

Ginkgo is a small-cap cell-engineering company whose revenue keeps shrinking: FY2025 revenue was $170.2M, down 25% from $227.0M the year before, and down further in the most recent quarter. Gross margin is a healthy 81%, but heavy R&D and overhead spending drove a $312.8M net loss and negative free cash flow of $178.7M. Cash sits at $302.2M against $404.1M of debt, and share count is up 6.9% YoY from stock sales.

What's Happening Right Now

• Tue 29th Sep '26 · Consortium: On Sept 29, 2026, Ginkgo Datapoints and Apheris launched an Antibody Developability Consortium with AbbVie, argenx, Lundbeck, and Takeda as founding members, targeting a 10,000-antibody dataset by early 2027.
• Wed 16th Sep '26 · Partnership: On Sept 16, 2026, Ginkgo Datapoints announced a partnership with Lilly's TuneLab platform to supply small molecule and antibody developability data for AI-driven drug discovery.
• Thu 10th Sep '26 · Contract: On Sept 10, 2026, Ginkgo was awarded a subcontract worth up to $17.5M under ARPA-H's GIVE program to help build an autonomous manufacturing system for individualized RNA medicines.
• Wed 9th Sep '26 · Earnings: Q2 2026 revenue fell about 48% to $20.2M as a large agriculture customer scaled back and fewer big pharma programs ran; net loss narrowed to $46.7M but cash fell to $84.5M from $167.2M, with $47M restricted until 2029.
• Mon 7th Sep '26 · Earnings: Ginkgo reaffirmed full-year 2026 cash burn guidance of $125M-$150M and highlighted new government lab contracts (NSF cloud lab initiative, a $47M EMSL contract) alongside 17 early customers for its ADME-One service.

Bottom Line

Ginkgo is a business in ongoing decline: revenue has fallen for three straight years and the most recent quarter dropped nearly 48% year over year, while losses remain large relative to sales. Signal8 models roughly 16.6 months of cash runway, and the company has been raising cash through stock sales, diluting existing shareholders. New government and pharma partnerships are notable data points, but nothing in the recent numbers shows the revenue decline has stopped.